Anti-tumor activity of obinutuzumab and rituximab in a follicular lymphoma 3D model

Blood Cancer Journal

Volumn 3, Issue 8, 2013, Pages

  Decaup, E ^a,b,c,d,e   Jean, C ^f   Laurent, C ^a,g   Gravelle, P ^a,b,c,d   Fruchon, S ^g   Capilla, F ^a   Marrot, A ^a   Al Saati, T ^a   Frenois, F X ^a   Laurent, G ^a,b,c,d   Klein, C ^h   Varoqueaux, N ⁱ   Savina, A ^j   Fournie J J ^a,b,c,d   Bezombes, C ^a,b,c,d  

^a CHU PURPAN   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c Institut Carnot Lymphome CALYM   (France)

^d Laboratoire d'Excellence Toulouse Cancer TOUCAN   (France)

^e Institut Roche de Recherche et Médecine Translationnelle   (France)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g University of Toulouse III   (France)

^h Roche Glycart AG   (Switzerland)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j Roche   (France)

more..

Author keywords

3D model; Follicular lymphoma; Monoclonal antibodies; Spatial organization

Indexed keywords

BENDAMUSTINE; BETA GALACTOSIDASE; CASPASE 3; CISPLATIN; CYCLIN A; CYCLIN B; CYCLIN D1; CYTOCHROME C; DOXORUBICIN; ETOPOSIDE; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OBINUTUZUMAB; PHOSPHOLIPASE C GAMMA; PROTEIN KINASE B; PROTEIN KINASE SYK; RAPAMYCIN; RITUXIMAB; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CANCER INHIBITION; CANCER MODEL; CELL AGGREGATION; CELL AGING; CELL DEATH; CELL STRUCTURE; CONTROLLED STUDY; CULTURE TECHNIQUE; DRUG EFFICACY; DRUG POTENTIATION; FOLLICULAR LYMPHOMA; IN VIVO STUDY; INTRACELLULAR SIGNALING; LARGE CELL LYMPHOMA; LYMPHOMA CELL; LYMPHOMA CELL LINE; LYSOSOME; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; OPTIMAL DRUG DOSE; SENESCENCE; TREATMENT RESPONSE;

EID: 84882997049     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.32     Document Type: Article

References (42)

1. Maloney DG. Treatment of follicular non-Hodgkin's lymphoma. Curr Hematol Rep 2005; 4: 39-45
2. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: Implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007; 26: 3629-3636 (Pubitemid 46842700)
3. Bezombes C, Fournié JJ, Laurent G. Direct effect of rituximab in B-cell-derived lymphoid neoplasias: Mechanism, regulation, and perspectives. Mol Cancer Res 2011; 9: 1435-1442
4. Witzig TE, Gupta M. Signal transduction inhibitor therapy for lymphoma. Hematology (Am Soc Hematol Educ Program) 2010; 2010: 265-270
5. Mahadevan D, Fisher RI. Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol 2011; 29: 1876-1884
6. Sawas A, Diefenbach C, O'Connor OA. New therapeutic targets and drugs in non-Hodgkin's lymphoma. Curr Opin Hematol 2011; 18: 280-287
7. Smith MR. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene 2003; 22: 7359-7368
8. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008; 20: 444-449
9. Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115: 4393-4402
10. Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009; 119: 2143-2159
11. Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM et al. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008; 112: 4170-4177
12. Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actindependent, lysosome-mediated cell death in B-cell malignancies. Blood 2011; 117: 4519-4529
13. Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood 2012; 119: 3523-3533
14. Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012; 119: 5118-5125
15. Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 2012; 119: 5126-5132
16. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P et al. Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas. Gastroenterology 2001; 121: 839-852 (Pubitemid 32962576)
17. Dangles-Marie V, Richon S, El-Behi M, Echchakir H, Dorothée G, Thiery J et al. A three-dimensional tumor cell defect in activating autologous CTLs is associated with inefficient antigen presentation correlated with heat shock protein-70 down-regulation. Cancer Res 2003; 63: 3682-3687 (Pubitemid 36793052)
18. Ghosh S, Spagnoli GC, Martin I, Ploegert S, Demougin P, Heberer M et al. Three-dimensional culture of melanoma cells profoundly affects gene expression profile: A high density oligonucleotide array study. J Cell Physiol 2005; 204: 522-531 (Pubitemid 40934647)
19. Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM et al. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog 2007; 46: 872-885 (Pubitemid 47549773)
20. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2010; 122: 35-43
21. Pickl M, Ries CH. Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab. Oncogene 2009; 28: 461-468
22. Gravelle P, Jean C, Valleron W, Laurent G, Fournié JJ. Innate predisposition to immune escape in follicular lymphoma cells. Oncoimmunology 2012; 1: 555-556
23. Sutherland R, Buchegger F, Schreyer M, Vacca A, Mach JP. Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res 1987; 47: 1627-1633 (Pubitemid 17044495)
24. Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G et al. Syk-dependent mTOR activation in follicular lymphoma cells. Blood 2006; 108: 4156-4162 (Pubitemid 44913287)
25. Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009; 4: 1798-1806
26. Irish JM, Czerwinski DK, Nolan GP, Levy R. Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol 2006; 177: 1581-1589 (Pubitemid 44092493)
27. Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK et al. B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci USA 2010; 107: 12747-12754
28. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature 2011; 469: 221-225Erratum in: Nature 2011; 475: 122
29. Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Mü ller S et al. Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 2004; 104: 1166-1173 (Pubitemid 39038039)
30. Däbritz JHM, Yu Y, Rosenfeldt MT, Dörken B, Schmitt CA. Anti-CD20 immunotherapy augments the chemotherapy-induced snescence response in human lymphoma cells. Blood (ASH Annual Meeting Abstracts) 2010; 182: (abstract 1827
31. Golay J, Bologna L, André PA, Buchegger F, Mach JP, Boumsell L et al. Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: Homotypic adhesion and flow cytometry result in artefactual direct cell death. Blood 2010; 116: 3372-3373
32. Leseux L, Laurent G, Laurent C, Rigo M, Blanc A, Olive D et al. PKC zeta mTOR pathway: A new target for rituximab therapy in follicular lymphoma. Blood 2008; 111: 285-291
33. Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A et al. Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther 2011; 10: 178-185
34. Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in chemosensitization and therapeutic intervention. Oncogene 2005; 24: 2121-2143 (Pubitemid 40516580)
35. Patz M, Isaeva P, Forcob N, Mü ller B, Frenzel LP, Wendtner CM et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011; 152: 295-306
36. Berinstein NL, Grillo-Ló pez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001 (Pubitemid 28496709)
37. Maloney DG. Follicular NHL: From antibodies and vaccines to graft-versuslymphoma effects. Hematology (Am Soc Hematol Educ Program) 2007 226-232
38. Daydé D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H et al. Tumor burden influences exposure and response to rituximab: Pharmacokineticpharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 2009; 113: 3765-3772
39. Hekimi S, Lapointe J, Wen Y. Taking a "good" look at free radicals in the aging process. Trends Cell Biol 2011; 21: 569-576
40. Turzanski J, Daniels I, Haynes AP. Involvement of macroautophagy in the caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Br J Haematol 2009; 145: 137-140
41. Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger MO et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011; 118: 358-367
42. Delbaldo C, Albert S, Dreyer C, Sablin MP, Serova M, Raymond E et al. Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors. Target Oncol 2011; 6: 119-124